No headlines found.
Globe Newswire (Tue, 25-Aug 1:00 AM ET)
Globe Newswire (Thu, 16-Jul 1:00 AM ET)
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
Globe Newswire (Wed, 15-Jul 1:00 AM ET)
Globe Newswire (Mon, 6-Jul 1:00 AM ET)
Globe Newswire (Thu, 2-Jul 1:00 AM ET)
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Molecular Partners Ag - American Depositary Shares trades on the NASDAQ stock market under the symbol MOLN.
As of September 15, 2026, MOLN stock price climbed to $4.20 with 3,667 million shares trading.
MOLN has a market cap of $157.08 million. This is considered a Micro Cap stock.
In the last 3 years, MOLN traded as high as $12.70 and as low as $3.32.
MOLN has underperformed the market in the last year with a price return of +12.9% while the SPY ETF gained +16.4%. MOLN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +2.2% and -1.9%, respectively, while the SPY returned +2.4% and -1.3%, respectively.
MOLN support price is $3.79 and resistance is $4.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MOLN shares will trade within this expected range on the day.